by Peter Ciszewski | Apr 28, 2018
Rob Neville of Savara Pharmaceuticals discusses some of the challenges of diangosing PAP and NTM lung infection, two diseases Savara targets. Molgradex is an inhaled formulation of recombinant human GM-CSF that is being developed for the treatment of autoimmune...
by Peter Ciszewski | Apr 27, 2018
Yuval Cohen, PhD, CEO of Corbus discusses current clinical trials of lenabasum for systemic sclerosis, dermatomyositis, systemic lupus erythematosus, and cystic fibrosis. Lenabasum is a synthetic, oral, small-molecule, selective cannabinoid receptor type 2...
by Peter Ciszewski | Apr 26, 2018
Porphyria refers to a group of disorders that result from a buildup of natural chemicals that produce porphyrin in your body. Porphyrins are essential for the function of hemoglobin — a protein in your red blood cells that links to porphyrin, binds iron, and carries...
by Peter Ciszewski | Apr 26, 2018
Justin Fallon, PhD is the Scientific Founder and Director of Tivorsan Pharmaceuticals, discusses his company’s plan for entering Biglycan into clinical trials and his compnay’s work with Duchenne Muscular Dystrophy (DMD) and Becker Muscular...
by Peter Ciszewski | Apr 25, 2018
Jan-Anders Karlsson discusses Verona Pharma’s lead candidate, RPL554, as a potential therapy for cystic fibrosis (CF). Verona Pharma is currently undertaking a comprehensive Phase 2 clinical trial programme for nebulized RPL554 as a maintenance treatment of COPD...
